Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis

New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative ...
TipRanks on MSN

Eli Lilly reports new data from LUCENT-URGE study

New data from Eli Lilly (LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis and bowel ...
Healio

And Your 2025 Healio Disruptive Innovators Are ...

Healio Gastroenterology and its collaborators unveiled the newest class of Disruptive Innovators Award recipients during the ...

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...